International Journal of Clinical Oncology

, Volume 23, Issue 2, pp 298–304 | Cite as

Repeat cytoreduction and hyperthermic intraperitoneal chemotherapy for recurrent peritoneal carcinomatosis of appendiceal origin

Original Article
  • 71 Downloads

Abstract

Background

The purpose of this study was to clarify the role of repeat cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS + HIPEC) in the management of recurrent peritoneal carcinomatosis of appendiceal origin.

Methods

Data were retrieved on 42 patients who underwent CRS + HIPEC; 29 repeat surgical procedures were performed in 13 patients.

Results

Complete cytoreduction was achieved in 12 of 13 patients by the second CRS. Repeat recurrence was detected in 11 patients, eight of whom underwent a third CRS. The peritoneal cancer index decreased from initial CRS to repeat CRS but was still higher than 18 in nine patients at the second CRS. Preoperative chemotherapy was given to three patients with early recurrence. Grade 3–5 morbidity and 90-day mortality were not significantly different between initial and repeat CRS. Five-year survival rates after first and second CRS were 75.5 and 67.7%, respectively. Complete cytoreduction at second CRS was a significant prognostic factor. Among patients with recurrence after the second CRS, patients who underwent a third CRS showed a better prognosis than those who did not.

Conclusions

Repeat CRS is oncologically beneficial, and the morbidity rate was as high as that of initial CRS. Complete cytoreduction was the key to successful long-term results. Although further recurrence was common, aggressive resection was useful, even in cases of diffuse recurrence.

Keywords

Repeat cytoreductive surgery Appendiceal cancer Diffuse recurrence Small intestine Multidisciplinary approach Third procedure 

Notes

Acknowledgement

The authors thank Prof. Takayoshi Hirai, Fukui Prefectural University, for confirming that methods of statistical analysis were correct.

Compliance with ethical standards

Conflict of interest

The authors have no conflicts of interest in association with this study.

References

  1. 1.
    Sugarbaker PH (2006) New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol 7:69–76CrossRefPubMedGoogle Scholar
  2. 2.
    Yan TD, Black D, Savady R et al (2007) A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol 14:484–492CrossRefPubMedGoogle Scholar
  3. 3.
    Chua TC, Moran BJ, Sugarbaker PH et al (2012) Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol 30:2449–2456CrossRefPubMedGoogle Scholar
  4. 4.
    Mogal H, Chouliaras K, Levine EA et al (2016) Repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: review of indications and outcomes. J Gastrointest Oncol 7:129–142PubMedPubMedCentralGoogle Scholar
  5. 5.
    Esquivel J, Sugarbaker PH (2001) Second-look surgery in patients with peritoneal dissemination from appendiceal malignancy: analysis of prognostic factors in 98 patients. Ann Surg 234:198–205CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Bijelic L, Yan TD, Sugarbaker PH (2008) Treatment failure following complete cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal dissemination from colorectal or appendiceal mucinous neoplasms. J Surg Oncol 98:295–299CrossRefPubMedGoogle Scholar
  7. 7.
    Lord AC, Shihab O, Chandrakumaran K et al (2015) Recurrence and outcome after complete tumor removal and hyperthermic intraperitoneal chemotherapy in 512 patients with pseudomyxoma peritonei from perforated appendiceal mucinous tumors. Eur J Surg Oncol 41:396–399CrossRefPubMedGoogle Scholar
  8. 8.
    Smeenk RM, Verwaal VJ, Antonini N et al (2007) Progression of pseudomyxoma peritonei after combined modality treatment: management and outcome. Ann Surg Oncol 14:493–499CrossRefPubMedGoogle Scholar
  9. 9.
    Delhorme JB, Honoré C, Benhaim L et al (2017) Long-term survival after aggressive treatment of relapsed serosal or distant pseudomyxoma peritonei. Eur J Surg Oncol 43:159–167CrossRefPubMedGoogle Scholar
  10. 10.
    Sardi A, Jimenez WA, Nieroda C et al (2013) Repeated cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from appendiceal cancer: analysis of survival outcomes. Eur J Surg Oncol 39:1207–1213CrossRefPubMedGoogle Scholar
  11. 11.
    Saxena A, Yan TD, Morris DL (2010) Critical assessment of preoperative and operative risk factors for complications after iterative peritonectomy procedures. Eur J Surg Oncol 36:309–314CrossRefPubMedGoogle Scholar
  12. 12.
    Mohamed F, Chang D (2003) Sugarbaker PH (1995) Third look surgery and beyond for appendiceal malignancy with peritoneal dissemination. J Surg Oncol 83:5–13CrossRefPubMedGoogle Scholar
  13. 13.
    Sugarbaker PH (1995) Peritonectomy procedures. Ann Surg 221:29–42CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Moran B, Baratti D, Yan TD et al (2008) Consensus statement on the loco-regional treatment of appendiceal mucinous neoplasm with peritoneal dissemination (pseudomyxoma peritonei). J Surg Oncol 98:277–282CrossRefPubMedGoogle Scholar
  15. 15.
    Ronnett BM, Yan H, Kurman RJ et al (2001) Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis. Cancer 92:85–91CrossRefPubMedGoogle Scholar
  16. 16.
    Chua TC, Quinn LE, Zhao J et al (2013) Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent peritoneal metastasis. J Surg Oncol 108:81–88CrossRefPubMedGoogle Scholar
  17. 17.
    Chua TC, Liauw W, Morris DL (2012) Early recurrence of pseudomyxoma peritonei following treatment failure of cytoreductive surgery and perioperative intraperitoneal chemotherapy is indicative of a poor survival outcome. Int J Colorectal Dis 27:381–389CrossRefPubMedGoogle Scholar
  18. 18.
    Konstantinidis IT, Levine EA, Chouliaras K et al (2017) Interval between cytoreductions as a marker of tumor biology in selecting patients for repeatcytoreductive surgery with hyperthermic intraperitoneal chemotherapy. J Surg Oncol.  https://doi.org/10.1002/jso.24703 PubMedGoogle Scholar
  19. 19.
    Pietrantonio F, Maggi C, Fanetti G et al (2014) FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma. Oncologist 19:845–850CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Bijelic L, Kumar AS, Stuart OA et al (2012) Systemic chemotherapy prior to cytoreductive surgery and HIPEC for carcinomatosis from appendix cancer: impact on perioperative outcomes and short-term survival. Gastroenterol Res Pract 2012:163284.  https://doi.org/10.1155/2012/163284 PubMedPubMedCentralGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2017

Authors and Affiliations

  1. 1.Department of SurgeryKishiwada City HospitalKishiwadaJapan

Personalised recommendations